Investors with a short-term perspective can consider buying the stock of Claris Lifesciences at current levels. The stock jumped 6.7 per cent with an above average volume, breaking above a key long-term resistance level of ₹365 on Thursday. This rally has strengthened the stock’s long-term uptrend that has been in place since the April 2016 low of around ₹130. Medium as well as the short-term tr...